ACUTE MYELOID LEUKEMIA

This study tested a new drug (MBG453) combined with two other medicines (azacitidine and venetoclax) for adults with acute myeloid leukemia who were too frail for standard chemotherapy. The goal was to see if the combination was safe and could lead to remission. The trial was ter…

This study tested a combination of three drugs—magrolimab, azacitidine, and venetoclax—in adults with acute myeloid leukemia (AML) that had come back or not responded to prior treatment. The goal was to find the best dose and see how well the drugs worked together to control the …

This study tested a treatment called TCB008 for people with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. TCB008 uses donated immune cells (gamma-delta T cells) grown in a lab to attack cancer cells. The trial aimed to see if these cells could…

This study looked at people with blood cancers receiving a stem cell transplant from an unrelated donor. The goal was to find which of two drug combinations (cyclosporine and sirolimus with either MMF or post-transplant cyclophosphamide) better prevents a serious side effect call…

This early-phase study tested a new drug called DSP107 combined with standard chemotherapy drugs (azacitidine with or without venetoclax) in adults with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic leukemia that had returned or not responded to up t…

This study tested whether a combination of venetoclax and azacytidine (or a DA regimen) could prevent relapse in adults with acute myeloid leukemia (AML) who still had measurable disease (MRD positive) after standard chemotherapy. The goal was to extend the time patients stayed i…

This study tested a new drug called CWP232291 combined with standard chemotherapy (cytarabine) in 15 adults with acute myeloid leukemia (AML) that had returned or not improved after prior treatments. The goal was to find a safe dose and see if the combination could shrink or elim…

This early-stage study tested two drugs, AZD1775 and belinostat, in 20 adults with certain blood cancers (like acute myeloid leukemia) that came back or didn't respond to prior therapy. The main goal was to find the safest dose and check side effects. The study was stopped early,…

This study tested a combination of two drugs, venetoclax and decitabine, in 235 people with certain blood cancers (like acute myeloid leukemia and high-risk myelodysplastic syndrome) that either came back or didn't respond to prior treatment, or in older adults who couldn't handl…

This study tested a drug called isatuximab added to standard chemotherapy for children aged 28 days to under 18 years whose leukemia (ALL or AML) had returned or stopped responding to treatment. The goal was to see if the combination could help achieve complete remission. The tri…

This early-phase study tested the safety and best dose of a drug called Minnelide in 27 adults with acute myeloid leukemia (AML) that had come back or not responded to standard treatments. The goal was to find the highest safe dose and see if it could help control the disease. Th…

This early-stage study tested a new drug called AUR103 Calcium in 27 adults with advanced cancers that had stopped responding to standard treatments. The goal was to find a safe dose and see how the drug worked in the body. The trial was terminated early, so no final results are …

This early-stage study tested a new drug called INKmune in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal was to see if it was safe and to find the best dose. Only 2 people took part before the study was stopped early.

This early-phase study tested a new cell therapy (LCAR-AMDR cells) in 4 people with acute myeloid leukemia that had come back or not responded to standard treatments. The therapy uses specially engineered immune cells to target two proteins on leukemia cells. The study was termin…

This study tested a special type of immune cell (MT-401) made from a donor's blood to treat acute myeloid leukemia (AML) after a stem cell transplant. The cells were designed to attack cancer cells while leaving healthy tissue alone. The trial aimed to see if this approach could …

This study tested a chemotherapy combination containing cladribine for people whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) had returned or not responded to prior treatment. The goal was to see if the treatment could wipe out signs of the disease …

This early-stage study tested a three-drug combination (uproleselan, azacitidine, and venetoclax) in 16 older or medically unfit adults with untreated acute myeloid leukemia (AML). The goal was to find the safest dose and check for side effects. The trial was terminated early, so…

This early-phase trial tested a new drug called SL-172154, given with standard chemotherapy drugs (azacitidine with or without venetoclax), in adults with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The study aimed to find a safe dose and check for…

This early-stage study tested a new drug called SGR-2921 in adults with relapsed or refractory acute myeloid leukemia or high-risk myelodysplastic syndrome. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.

This study tested a drug called sabatolimab in 24 adults and teens with acute myeloid leukemia who still had small amounts of cancer cells after a stem cell transplant. The goal was to see if sabatolimab, alone or with another drug, could prevent the leukemia from coming back wit…

This early-stage study aimed to see if an oral (pill) form of the chemotherapy drug cladribine works similarly to the standard IV (intravenous) version in people with certain blood cancers like leukemia. Only 3 people took part before the study was stopped early. The main goal wa…